No Data
No Data
IBio, Mesoblast, Kodiak Sciences Among Healthcare Movers
BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment
BeyondSpring (BYSI) said Monday that the first patient has been dosed in a phase 2 investigator-initiated trial of pembrolizumab, plinabulin plus etoposide/platinum for first-line extensive-stage smal
BeyondSpring Announces First Patient Dosed With Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
BeyondSpring Inc. (NASDAQ: BYSI) today announced that the first patient has been dosed in a Phase 2 investigator-initiated trial (IIT) with Pembrolizumab, Plinabulin, BeyondSpring's lead asset, plus Etoposide/Platinum (EP) for first-line (1L) Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) [NCT05745350].
BeyondSpring Announces Executive Leadership Change
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersPsyence Biomedical (NASDAQ:PBM) stock moved upwards by 35.3% to $1.38 during Thursday's regular session. The market value of their outstanding shares is at $18.4 million. ZyVersa Therapeutics (
BeyondSpring, EnVVeno Medical, Aptorum Group Among Healthcare Movers
No Data